Boston, MA 10/28/2013 (wallstreetpr) – Allerayde SAB, Inc. (OTCMKTS:ASAB) is healthcare company based in the U.S. and the U.K and it specializes in the development and marketing of allergy solutions for consumer and professional sector. The management of allergy, eczema and anaphylaxis is the core business of ASAB. Relying on a management team with over 30 years experience in this line of healthcare, it can be seen that the company has the potential to pursue the lion’s share of $64.6 billion annual spending on prescription allergy medications. The company’s lean workforce is also a key strength in itself as it means lower operation costs and maximum earnings for the investors.
Studies reveal that more than 40% of the global population is affected by allergy, and these figures have been on the increase for the past 40 years. For the allergy affected population, the commonly encountered symptoms are such as eczema, rhinitis and asthma. While there are medication solutions for allergy sufferers, the treatment is usually costly. And also, a lot of medications bear unwanted side effects. This is why ASAB’s innovative solution for allergy sufferers which comes in the form of fabrics and medication are resonating well with the professional and individual consumers of allergy solutions.
ASAB has developed a microfiber fabric called Allerayde Lite which ensures that exposure to allergy agents in and bedding is minimized. This fabric is not only particle proof, but it is also soft to touch, durable and highly breathable. And for the eczema sufferers, ASAB has Exalon, yet another innovative fabric. The fabric has proven efficacy of up to 80% in terms of symptom reduction. This means that ASAB has been able to knock off competition in this line. The company is also working on another top-of-the class fabric called Derma-Chi which will be its latest addition to the allergy management market.
To better help allergy sufferers get over this nuisance, ASAB has developed an auto-injector called AAA Pen which despite being just half the price of the other allergy medication on the market, is able to give patient the best relief they need when asthma, eczema or rhinitis attack.
ASAB’s shares is trading at $0.455 up by 3.41% in its current session.
